Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.81 (market cap $5.86B), while Zimmer Biomet Holdings Inc trades at $88.85 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.9× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| JNK | ZBH | |
|---|---|---|
Market Cap | $5.86B | $16.95B |
Volume | 7,780,002 | 2,505,240 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $103.98 |
52-Week Low | $92.30 | $79.58 |
Typical Hold Time | 61 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK (SPDR Bloomberg High Yield Bond ETF) trades at $92.81 with minimal daily movement (+0.05%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains consistent dividend payments of $0.53 per share. Recent news highlights institutional interest with Envestnet Asset Management increasing its stake by 23.3% during the latest quarter.
The outlook for JNK is challenged by rising bond yields and macroeconomic uncertainty. While consistent dividends provide income appeal, the bearish technical setup and high-yield bond sensitivity to interest rate hikes present near-term risks. Institutional accumulation suggests long-term confidence, but investors should monitor credit market conditions closely.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
